what is known and what this paper adds: Misoprostol has been widely used in Obstetrics and Gynecology; however, its usefulness and efficacy in facilitating IUD insertion in nulligravidas have yet to be established. The present study shows that the benefits of misoprostol use prior to IUD insertion include facilitating insertion and reducing pain during the procedure; therefore, weighing up the benefits encountered against the only negative side effect (cramps prior to insertion), these results suggest that misoprostol use should become standard practice to facilitate IUD insertion in nulligravidas. study design, size duration: A randomized, double-blind clinical trial was conducted. participants/materials, setting methods: Nulligravid women of reproductive age were submitted to IUD insertion between July 2009 and November 2011 at the Instituto de Medicina Integral Prof. Fernando Figueira in Recife, Pernambuco, Brazil. A total of 179 women were randomly allocated to two groups: 86 to receive 400 mg of misoprostol vaginally 4 h prior to IUD insertion and 93 to receive placebo. Risk ratios (RRs) were calculated as measures of relative risk, together with their 95% confidence intervals (95% CI). The number needed to treat (NNT) and the number needed to harm (NNH) were also calculated.
Introduction
The intrauterine device (IUD) is a safe, extremely effective and longacting reversible contraceptive (LARC). Nevertheless, only 15% of women of reproductive age in developing countries and 8% in developed countries use it as a contraceptive method (d'Arcangues, 2007) . It is possible that difficulty in inserting the device limits its use in nulligravidas (Grimes and Schulz, 2001) .
Until a short time ago, it was assumed that the IUD should not be used in nulligravidas, since this contraceptive method was believed to be associated with an increased risk of pelvic inflammatory disease (PID) that could result in infertility (Hubacher et al., 2001) . Although recent studies have conducted more thorough evaluations of this association, and have concluded that the risk of infection is small so that nulliparity is no longer a contraindication to the use of the method, many healthcare professionals (HCPs) still limit its use in this group of women, claiming that insertion of the device is difficult (Grimes and Schulz, 2001) .
In an attempt to improve the ease of IUD insertion in nulligravidas, some investigators tested the use of misoprostol prior to the procedure (Schaefer et al., 2010; Dijkhuizen et al., 2011) . A recent clinical trial evaluated the use of 400 mg of misoprostol sublingually 90 min prior to IUD insertion in 40 nulligravidas. No significant difference in the pain reported by the woman was found when compared with controls (Edelman et al., 2011) . Another two studies also failed to show any reduction in pain or in the degree of difficulty in inserting the IUD (Scavuzzi et al., 2009; Heikinheimo et al., 2010) . Nevertheless, the protocol design in these three studies may have affected the results.
No consensus has yet been reached in the literature with respect to the efficacy, dose, timing and route of administration of misoprostol prior to IUD insertion. The objective of the present study was to determine whether the use of vaginal misoprostol prior to IUD insertion facilitates the procedure and reduces the women' perception of pain, as well as the immediate and late side effects.
Materials and Methods
A randomized, double-blind clinical trial was conducted involving nulligravid women of reproductive age submitted to insertion of an IUD (TCu 380 A, Optima, Injeflex, São Paulo, Brazil) with prior use of vaginal misoprostol (400 mg) or placebo at the Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil between January 2009 and November 2011. The study protocol was approved by the institution's review board and all women signed an informed consent prior entering the study. The study protocol was registered at ClinicalTrials.gov under reference number NCT01383889. The study protocol and Consort checklist are available as Supplementary data.
Sample size was calculated using the OpenEpi software program, version 2.3.1, considering a frequency of subjective difficulty in inserting the IUD of 45% in the placebo group and a 50% reduction in this rate with the use of misoprostol (Sääv et al., 2007) . According to the calculation, 152 women would be necessary (76 women in each group). Predicting losses or cases of protocol violation of up to 20%, this number was increased and, as a safety measure, 190 boxes of the study medication containing misoprostol or placebo were prepared.
Nulligravidas of reproductive age who had never been submitted to surgery of the uterine cervix and who had requested to use an IUD as a contraceptive method were included in the study. Women with a contraindication to the use of an IUD as defined in categories 3 and 4 of the World Health Organization's (2004) medical eligibility criteria (2004) for contraceptive use were excluded from the study.
The women were initially identified at the family planning clinic of IMIP's Women's Healthcare Center (CAM). During the IUD insertion, all women were menstruating. The day of the menstrual cycle for IUD insertion ranged from first to ninth. At that time, the women were randomized to the vaginal misoprostol (400 mg) group or placebo group. The tablet was introduced by the principal investigator into the posterior vaginal fornix of the woman 4 h prior to IUD insertion. All insertions were performed by the principal investigator using the standard technique (Edelman et al., 2011) .
The IUD used was the copper T380A (Optimaw) and all insertions were performed by the principal investigator, using the standard technique for IUD insertion (Edelman et al., 2011) .
Each woman was identified by a sequential ordinal number corresponding to a sealed box containing either two tablets of placebo or two tablets each containing 200 mg of misoprostol. In addition to the sequential number, each box was identified with the woman's name and registration number, and was only opened when the tablets had to be inserted into the vagina. Neither the investigator nor the woman was aware if misoprostol or placebo was to be administered. Randomization was carried out (1:1) in accordance with a list created using the block randomization method and containing sequential numbers from 1 to 190 (the number of women to be randomized). This list was prepared by a statistician not directly involved in the study, using the Random Allocation Software program, version 1.0 (Isfahan, Iran) and using only the letters A and B, without being aware of their meaning. This list was sent to the pharmaceutical company, where the coding (misiprostol or placebo) of each letter, A and B, was randomly selected. The boxes were prepared by the pharmacist in accordance with the randomization established by the statistician. The investigators were aware of the contents of boxes A and B, only after the statistical analysis was complete when the randomization code was broken and the coding of each letter was revealed.
The vaginal misoprostol tablets at the dose of 200 mg each, a total dose per woman of 400 mg, were commercialized and developed specifically for vaginal use by Hebron Indústria Farmacêutica (Caruaru, Pernambuco, Brazil) according to good manufacturing practice, who also prepared the placebo tablets, which were identical to the active drug in shape, size, color and weight, and were made specifically for this study.
The primary end point was the subjective difficulty (as reported by the investigator) in inserting the IUD. Secondary end points were the frequency of women with cervical dilation ≤4 mm (measured by inserting a #4 Hegar dilator through the internal orifice of the cervix uteri immediately prior to IUD insertion) and pain at insertion, as judged subjectively by the woman and evaluated by the investigator using a visual analog scale (Sääv et al., 2007) . The scale ranged from 0 to 10, in which 0 is the absence of pain and 10 the worst pain imaginable. The scores were later dichotomized into absent/mild (0 -5) and moderate/severe (6 -10). A further secondary end point was the woman's subjective evaluation of the procedure (IUD insertion), classified as not disagreeable, slightly disagreeable, disagreeable or very disagreeable.
The frequency of immediate side effects (those occurring prior to IUD insertion) and late side effects (those occurring 24 h after IUD insertion) (cramps, nausea, vomiting, diarrhea and hyperthermia) was also evaluated, as well as the side effects that occurred during IUD insertion such as cramps, nausea, vomiting, vasovagal reaction, uterine perforation and failure to insert the device. We requested information about the 24 h events by phone calls. We explained how they should measure the temperature and we provided a thermometer if they did not have one.
Thirty days after IUD insertion, the women were contacted by telephone and requested to attend the gynecology clinic to evaluate complications such as heavy menstrual bleeding, intermenstrual bleeding, spotting, the intensity of cramps, candidiasis, bacterial vaginosis and IUD expulsion. Whenever any complication was identified, the appropriate treatment was provided.
The analysis was conducted under the intention-to-treat principle. Initially, the distribution tables of frequency were constructed for the categorical variables, and measures of central tendency and dispersion were calculated for the numerical variables. The x 2 test of association and Fisher's exact test were used, as appropriate, to determine the association between the variables and the use of misoprostol or placebo. Two-tailed values were used for all the tests. Risk ratios (RR) were calculated as a measure of relative risk, together with their relevant 95% confidence intervals. The number needed to treat (NNT) and the number needed to harm (NNH) were also calculated, together with their respective 95% confidence intervals.
Results
Initially, the IUD was offered as a contraceptive method to 220 nulligravid women, 30 of whom were excluded from the study. Of these, 16 did not fulfill the inclusion criteria (never having been pregnant and never having undergone any surgical procedure of the uterine cervix) and 14 were excluded for other reasons (the presence of purulent cervicitis, vaginal bleeding of undefined cause and submucous myomas deforming the uterine cavity). Ten women refused to participate in the study. Therefore, 190 women were randomized, 95 to the placebo group and 95 to the vaginal misoprostol group. Following randomization, eight boxes containing misoprostol and two containing placebo were accidentally damaged and could no longer be used. Of the 87 women remaining in the misoprostol group, 1 woman discontinued the study after having been given the medication; therefore, 179 nulligravid women remained in the study, 86 in the vaginal misoprostol group and 93 in the placebo group (Fig. 1 ). There were no significant differences between the two groups with respect to the characteristics of the women in the sample (Table I) . Significant differences were found between the groups for all the immediate end points evaluated, with less difficulty in inserting the IUD (RR ¼ 0.49; 95% CI: 0.33 -0.72; NNT ¼ 3; P ¼ 0.00001) and less risk of cervical dilatation ≤4 mm (RR ¼ 0.49; 95% CI: 0.33 -0.70; NNT ¼ 4; P ¼ 0.00005) when misoprostol was used prior to insertion. The group of women submitted to prior use of misoprostol also had a 44% reduction in moderate-to-severe pain during IUD insertion compared with the placebo group (RR ¼ 0.56; 95% CI: 0.41 -0.76; NNT ¼ 3; P ¼ 0.00004). Likewise, fewer women reported a subjective sensation of a disagreeable or very disagreeable experience with the use of misoprostol (RR ¼ 0.49; 95% CI: 0.35 -0.68; NNT ¼ 3; P ¼ 0.000004) (Table II) .
There were no significant differences between the groups in relation to complications during IUD insertion. The frequency of bleeding, vasovagal reaction, cramps, nausea, vomiting and insertion failures was similar in both groups. No cases of uterine perforation occurred in either group (Table III) .
There were no significant differences in the frequency of the majority of the immediate side effects such as nausea, vomiting, hyperthermia and diarrhea, evaluated prior to IUD insertion. Nevertheless, there was a significant increase in cramps with the prior use of misoprostol compared with placebo (RR ¼ 1.40; 95% CI: 1.05-1.86; NNH ¼ 6; P ¼ 0.002). In relation to the side effects evaluated 24 h after IUD insertion, no significant differences were found between the misoprostol and placebo groups (Table IV) .
Because insertion of the device failed in some cases, the evaluation conducted 30 days later included 82 women in the misoprostol group and 90 in the placebo group. No significant differences were found between the two groups when the frequency of heavy menstrual bleeding, intermenstrual bleeding, spotting, cramps, PID or expulsion rates were compared (Table V) .
Discussion
In the present study, prior use of misoprostol at a dose of 400 mg was found to be associated with less subjective difficulty in inserting the IUD in nulligravidas, less risk of cervical dilatation ≤4 mm and less pain, as reported by the women; however, there was a greater incidence of cramps.
The effect of misoprostol on the cellular matrix of the uterine cervix causes dissolution of collagen fibers, increasing the amount of fluid in the stroma and consequently causing cervical effacement. This effect makes use of this drug a feasible proposition for certain gynecological and obstetrical conditions (Fiala et al., 2007; Tang et al., 2002; Tang et al., 2007) .
Some studies have already been conducted to seek scientific evidence in support of using misoprostol prior to IUD insertion in nulligravidas; however, the variation in the doses, timing of administration and routes of administration render comparison of these results difficult (Li et al., 2005; Sääv et al., 2007; Dijkhuizen et al., 2011) . Furthermore, small sample sizes may have been responsible for the lack of any significant effects found in some studies. Despite the different timing and routes of administration, the present findings are in agreement with the results published by other authors with respect to the degree of difficulty at insertion (Li et al., 2005; Sääv et al., 2007) . However, some studies failed to find any reduction in pain during the procedure and found no increase in the likelihood of insertion being successful (Schaefer et al., 2010; Dijkhuizen et al., 2011) .
Two of the principal findings of the present study were the easier insertion of the IUD and the greater likelihood of cervical dilatation .4 mm with the prior use of misoprostol. Other investigators have reported similar results (Li et al., 2005; Sääv et al., 2007) . In one clinical trial, the authors reported that sublingual administration of 400 mg of misoprostol 1 h prior to IUD insertion in 47 nulligravidas women made insertion significantly easier and reduced the rates of insertion failure (Sääv et al., 2007) . In another study involving a small series of cases in which insertion failed due to cervical stenosis, the use of 400 mg of misoprostol vaginally resulted in successful insertion in all the women involved, suggesting greater ease of insertion of the IUD with the prior use of misoprostol (Li et al., 2005) .
A recently published clinical trial in which 400 mg of misoprostol was used orally 90 min prior to IUD insertion in 35 nulligravidas found no significant difference in the pain reported by the women (Edelman et al., 2011) . In that study, a greater frequency of side effects, particularly cramps and nausea, was found in the misoprostol group. The finding of a greater frequency of cramps is not surprising, since this side effect is caused by the increase in uterine contractility provoked by misoprostol, which is a potent prostaglandin (Arias, 2000; Tang et al., 2007) . In the present study, a greater frequency of cramps was also found in the group of women who received misoprostol, although no significant difference was found in relation to the other side effects (nausea, vomiting, diarrhea and hyperthermia). A question asked by several authors is could this increase in uterine contractions lead to an increased risk of expulsion of the device and this remains to be clarified (Edelman et al., 2011) . No evidence of this was found in the present study; however, the sample was inadequately powered to reveal any differences in expulsion rates between the groups.
IUD is a safe, effective, LARC method and it is currently considered an ideal contraceptive for young, nulligravid women, from the moment at which they initiate their sexual life until they decide to have their first child (American College of Obstetricians and Gynecologists, 2007) . In the past, the IUD was indicated only for multiparas, this recommendation probably originating from misgivings regarding a possible increase in the incidence of acute PID and the association between this condition and infertility. Although all subsequent studies have confirmed that this risk is low, many HCPs still discourage women who have never been pregnant from using this contraceptive method (Hubacher et al., 2001; Morgan, 2006; Stanback and Shelton, 2008) .
Another factor that limits use of the IUD in nulligravidas is that insertion could be technically more difficult and more painful in this group. Despite the lack of scientific evidence, misoprostol has been used and is recommended by many HCPs to facilitate this procedure. One study recently published in the USA evaluated the opinion of 2211 physicians working in the field of reproductive medicine. Overall, 1905 (86%) of the individuals interviewed reported inserting IUDs in nulligravidas and, of these, 947 (42.7%) use misoprostol prior to the procedure, with the majority (n ¼ 515; 54%) believing that the use of this medication greatly facilitates insertion of the device (Ward et al., 2011) . To the best of our knowledge no other study has been published in which 400 mg of misoprostol was used vaginally 4 h prior to IUD insertion. In other studies, doses have ranged from 100 to 800 mg, while the drug has been administered sublingually, orally, vaginally and rectally, and the timing of administration has ranged from 1 to 12 h prior to the procedure (Scavuzzi et al., 2009; Schaefer et al., 2010; Dijkhuizen et al., 2011; Edelman et al., 2011) . When selecting the vaginal route of administration and the moment of administration prior to IUD insertion, the pharmacokinetics of the drug were taken into consideration as a function of the different routes of administration, with an interval of 4 h being considered the most appropriate.
A peak misoprostol concentration occurs in ,30 min when the drug is used orally or sublingually and decreases rapidly from this moment on. On the other hand, when the vaginal route is used, the peak plasma concentration occurs after 1 h and its decrease is gradual, with levels remaining high for at least 6 h, at substantially higher levels than when administered by the oral or sublingual routes (el-Refaey et al., 1995; Aronsson et al., 2004) . When administered by the vaginal route, the side effects of misoprostol are milder and more self-limiting compared with the oral route, with less nausea, cramps and hyperthermia (Hamoda et al., 2004; Fiala et al., 2007) . A pilot study conducted in this institute using the same dose of 400 mg 1 h prior to IUD insertion in 30 nulligravidas women found no significant differences between the misoprostol and placebo groups, and that finding was also taken into consideration in designing the protocol of the present study. Therefore, regarding timing of administration, it was decided to increase the interval to 4 h in an attempt to reach a balance between achieving the maximum effect of misoprostol with as few side effects as possible (Scavuzzi et al., 2009 ). In addition, there was no significant difference between the groups with regard to complications during IUD insertion.
The major question to be discussed appears to be whether the benefits of the use of this drug outweigh the side effects presented, since IUD insertion, as evaluated by the professionals, is generally a simple procedure, with few women requiring cervical dilatation, paracervical block or to be submitted to an ultrasound-guided procedure (Allen et al., 2009) .
On the other hand, it should be taken into consideration that although IUD insertion is a simple, inexpensive, fast procedure performed on an outpatient setting and with low complication rates, even in nulligravidas (Bahamondes et al., 2011) , many women report pain during insertion and for this reason often opt for other methods that are less effective or irreversible (Forthofer, 2009) .
In an attempt to evaluate the actual benefits of the use of misoprostol in clinical practice, the NNT was calculated for the beneficial end points in the present study. It was found that for every three IUD insertions, with the prior use of misoprostol one woman would have an easier procedure and for every four IUD insertions one woman would classify the subjective sensation as not disagreeable or only slightly disagreeable. In addition, the NNH for cramps was 6, i.e. although side effects are common, there is a favorable counterbalance. Since the use of misoprostol in Brazil is limited to hospitals it is possible that recommending use of misoprostol prior to IUD insertion in nulligravidas will indeed be detrimental to the overall use of the device. We are aware that in family planning or in adolescent contraception it is important to start a contraceptive method at the initial consultation if the woman meets the eligibility criteria for the chosen method.
Therefore, since misoprostol is an inexpensive, safe, easily administered drug with few side effects, it would appear more sensible to suggest that the relevant authorities allow it to be used on an outpatient setting. The HCP would then be able to use this drug in the group of women in whom he/she deems it necessary, thus reducing the sensation of pain reported by the women and facilitating IUD insertion. Even when access to misoprostol is denied, however, nulliparity does not represent a contraindication to the use of the IUD and IUD insertion should not depend on the use of this medication.
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